Next Article in Journal
Neoadjuvant, Adjuvant and Perioperative Treatment in Early-Stage Non-Small Cell Lung Cancer (NSCLC) with Actionable Genomic Alterations: Current Landscape and Future Perspectives
Previous Article in Journal
MRI-Based Radiomics for Non-Invasive Prediction of Molecular Biomarkers in Gliomas
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 18
Issue 3
10.3390/cancers18030492
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Frequency of Founder Mutations in BRCA1 and BRCA2 Genes in Hereditary Breast Cancers in Poland vs. Other Countries

by
Beata Kulikowska
1,*,
Barbara Panasiuk
1 and
Renata Posmyk
1,2
1
Department of Clinical Genetics, Medical University of Bialystok, 15-089 Bialystok, Poland
2
Podlaskie Center of Clinical Genetics “Genetics”, 15-224 Bialystok, Poland
*
Author to whom correspondence should be addressed.
Cancers 2026, 18(3), 492; https://doi.org/10.3390/cancers18030492
Submission received: 4 January 2026 / Revised: 25 January 2026 / Accepted: 27 January 2026 / Published: 2 February 2026
(This article belongs to the Section Cancer Causes, Screening and Diagnosis)
Browse Figures
Versions Notes

Simple Summary

Hereditary breast cancer (HBC) accounts for a notable proportion of all breast cancer (BC) cases and is strongly associated with pathogenic variants (PVs) in the BRCA1 and BRCA2 genes. In several populations, certain BRCA PVs occur more frequently due to founder effects, reflecting their origin from a common ancestor and subsequent spread within specific regions. Understanding these population-specific founder mutations is essential for improving diagnostic accuracy, genetic counseling, and personalized surveillance strategies. In Poland, a distinct spectrum of BRCA1 and BRCA2 founder mutations has been identified, influencing national testing protocols and allowing more efficient identification of individuals at high genetic risk. This review summarizes current knowledge on the prevalence of founder mutations in Poland compared with neighboring countries, highlights their clinical implications, and emphasizes the crucial role of genetic counseling in prevention, risk assessment, and therapeutic decision-making for hereditary breast cancer.

Abstract

Breast cancer (BC) remains one of the most prevalent malignancies worldwide, and genetic factors may influence its development. Approximately 10–15% of all BCs are hereditary and known as Hereditary Breast Cancer (HBC). A remarkable family history and young onset are the strongest risk factors of HBC. The rapid development of genetic testing techniques has increased the detection rate of pathogenic and likely pathogenic variants in several genes associated with high, moderate, or low risk of HBC. This allowed us to identify the whole family at risk of HBC. Among hereditary cases, pathogenic variants (PVs) in the BRCA1 and BRCA2 genes are particularly notable, especially in certain populations where founder mutations (specific genetic variants originating from a common ancestor) are more prevalent. In this article, an overview of the current state of knowledge on HBC is provided, focusing on the frequency of founder mutations in the BRCA1 and BRCA2 genes in HBC in Poland compared to other countries. We will also highlight the role of genetic counseling in the diagnosis and treatment of BC, emphasizing its crucial importance in identifying genetic predispositions, selecting appropriate therapeutic strategies, and supporting patients and their families in making informed medical decisions.

1. Introduction

Breast cancer (BC) is the second most commonly diagnosed malignancy worldwide, behind only lung cancer. In women, BC is the most common type of cancer on a global level [1]. In 2022, BC affected 2.3 million women worldwide, resulting in 670,000 deaths. In developed countries, one in eight women will develop BC, and the average age of diagnosis is about 61 years [2]. Europe accounts for 24.3% of all BC cases [3]. In Poland, the crude rate of BC is 107.40 per 100,000, which is relatively low by European standards [1,4]. A significant increase in the incidence has been observed in recent decades, which is associated with both changes in women’s lifestyles and advances in diagnostic techniques that allow earlier detection of breast cancer.
Despite expanding knowledge about BC over the years, scientists are still unable to determine the main cause of breast cancer conclusively. However, much research on BC has isolated risk factors that may increase the incidence of BC. These factors can be both modifiable and non-modifiable. Factors beyond our control include gender, age, race, and family history of risk. Leading non-modifiable risk factors also include a low number of pregnancies, childlessness, first birth at a late age, a short breastfeeding period, early menarche, and late menopause [5,6,7]. Lifestyle also has a substantial impact on the incidence of BC. Among the modifiable risk factors for BC, we can include: alcohol consumption, smoking, physical activity, diet, and use of contraceptives [8,9,10]. A schematic overview of breast cancer risk factors is presented in Figure 1.
Hereditary breast cancer (HBC) accounts for approximately 5–10% of all BC cases, highlighting its significant role as a distinct subgroup of the disease [11]. Pathogenic variants (PVs) in the BRCA1 and BRCA2 genes play a pivotal role in the pathogenesis of HBC and are among the most well-studied and thoroughly characterized. Beyond BRCA1 and BRCA2, other, rarer gene PVs, such as CHEK2, PALB2, TP53, PTEN, and ATM, also contribute to an increased risk of BC. Each of these genes plays a crucial role in essential cellular processes, including DNA repair, cell growth regulation, and tumor suppression. When mutations occur, these processes are disrupted, raising the risk of cancer. Understanding the full range of gene PVs that contribute to BC risk is crucial for developing effective screening and prevention strategies [12,13,14,15,16,17].
Founder mutations in the BRCA1 and BRCA2 genes represent a unique genetic phenomenon observed in various populations worldwide. These mutations are so named because they originate from a common ancestor and are subsequently passed down through generations within a specific population or ethnic group. As a result, certain populations may exhibit a higher frequency of specific BRCA1 or BRCA2 mutations, known as founder mutations, compared to the general population. Understanding the prevalence and distribution of these founder mutations is crucial for providing accurate genetic counseling, assessing risk, and implementing targeted screening strategies in affected communities [18,19,20,21].

Family Risk

Familial risk is a very important factor associated with BC. Research shows that having relatives with breast or ovarian cancer (OC) dramatically increases the risk of developing this cancer. This risk increases proportionally with the number of close relatives (first-degree relatives: mother, sister, daughter) diagnosed with BC. Epidemiological studies have shown that having a close relative with BC doubles the risk of developing the disease compared to the general population. In cases where more than one close relative has breast cancer, this risk increases even further [22,23].
Data from the Generations Study, which included over 113,000 women from the UK, demonstrated that women with a higher FHS (Family History Score) had a significantly increased risk of developing BC. Specifically, those in the highest FHS group had a 3.5-fold increased risk compared to those with no family history of BC. Additionally, the study found that combining the FHS with the age of the youngest relative diagnosed with BC provided an even stronger predictor of risk [24]. A representative pedigree of a family with breast and ovarian cancer is presented in Figure 2.

2. Methodology

Comprehensive electronic literature search was conducted on legitimate databases including PubMed, Web of Science, MEDLINE and Google Scholar using the key-words “hereditary breast cancer”, “breast cancer”, “BRCA1”, “BRCA2”, “BRCA mutation”, “founder mutations”, “BRCA mutation in Poland”, and “germline mutations”. Both original research articles and review papers were included. The search covered research papers until 2025 in English. The search identified 281 articles, of which 185 were screened, and 115 were fully read. The findings of the review were synthesized and summarized in a narrative format.
The present review was conducted as a narrative overview of the available literature. While a broad and structured search of multiple databases was performed, the review did not follow a fully systematic methodology with protocol registration (e.g., PROSPERO). Therefore, the findings should be interpreted as a qualitative synthesis of current knowledge, aiming to highlight prevailing trends and population-specific patterns rather than to provide an exhaustive quantitative assessment.

3. Hereditary Breast Cancer

The concept that breast cancer (BC) can be inherited and passed from generation to generation was first described by Paul Broca in 1866 [25]. In 1994 and 1995, respectively, the two major BC susceptibility genes BRCA1 and BRCA2 were discovered, confirming the link between family history and the presence of hereditary genetic events that predispose individuals to develop BC [26,27]. In the past two decades, since the discovery of the BRCA genes, significant progress has been made in identifying further pathogenic germline variants (PVs) in BC susceptibility genes. A substantial proportion of hereditary breast cancer (HBC) cases are due to germline PVs in the BRCA1 and BRCA2 genes, which are responsible for the highest risk of BC. Germline PVs in other genes, such as TP53, NBN, PALB2, CHEK2, PTEN, CDH1, and ATM, are also associated with a high or intermediate risk of BC [28]. The distribution of germline pathogenic variants across breast cancer susceptibility genes is summarized in Figure 3.

3.1. Location and Function of BRCA1/2 Genes

The BRCA1 gene is situated on the long arm of chromosome 17 at locus 17q21. It spans approximately 81 kilobases of genomic DNA and includes 24 exons that code for a protein consisting of 1863 amino acids [26,34,35].
The BRCA2 gene is located on the long arm of chromosome 13 at locus 13q12.3. It encompasses approximately 84 kilobases of genomic DNA and comprises 27 exons, encoding a protein of 3418 amino acids [34,36].
BRCA1 and BRCA2 are crucial tumor suppressor genes whose PVs are strongly associated with hereditary breast and ovarian cancers (HBOC). Their functions span DNA repair, transcriptional regulation, and cell cycle control, playing an integral role in maintaining genomic stability [35,37,38,39,40].

3.2. Cancer Risk in BRCA1/2 Pathogenic Variant Carriers

Pathogenic variants (PVs) in the BRCA1 and BRCA2 genes significantly increase the risk of various cancers. The most well-established associations of BRCA1 and BRCA2 PVs are with breast and ovarian cancers (OC). Women with BRCA1 PVs have a 46–87% lifetime risk of BC and a 39–63% risk of OC. Similarly, BRCA2 PVs confer a 38–84% risk of BC and a 16.5–27% risk of OC. In addition to breast and ovarian cancer, BRCA1 and BRCA2 PVs are also associated with an increased risk of other malignancies, including pancreatic, prostate, and stomach cancers [41,42,43,44,45,46,47].
Another study of 3886 women shows that the risk of developing BC by the age of 80 is approximately 72% for BRCA1 PV carriers and about 69% for BRCA2 PV carriers [48].
Both BRCA1 and BRCA2 PVs are linked to an increased risk of male BC, although the risk is higher for BRCA2 PV carriers. Men with BRCA2 PVs have a relative risk (RR) of 44.0, corresponding to a cumulative risk of up to 3.8% by the age of 80, whereas BRCA1 PV carriers have an RR of 4.30 and a cumulative risk of approximately 0.4% [43].

4. Prevalence of BRCA1 Founder Mutations

The frequency of heterozygous carriers of germline pathogenic variants (PVs) in the BRCA1 gene in the general White population is estimated to be between 1/500 [49] and 1/1000 [50]. Mutations in the BRCA1 gene are scattered along the entire coding sequence. Among the identified alterations are deletions and insertions (~79%), which lead to a change in the reading frame; loss-of-function mutations (~20%), resulting in premature translation termination and the formation of a truncated protein; and sense-change mutations (up to 5%). Some of these mutations are common, while others are rare, unique, or are so-called polymorphisms of as yet unproven pathogenicity.
According to the Breast Cancer Information Core database (BIC) [51], approximately 2000 different BRCA1 gene alterations have been recognized to date.
It has been observed that in certain populations with a specific geographical location or ethnicity, certain mutations recur relatively frequently, which is related to the so-called founder effect. Examples of such variations are mutations found in Iceland [52], the Bahamas [53], the French province of Canada (Quebec) [54], Denmark [55], Sweden [56] or Norway [57]. According to BIC data, two mutations predominate among all mutations within the BRCA1 gene, namely c.68_69delAG (185delAG) in exon 2 (59%) and c.5266dupC (5382insC) in exon 20 (31%) [51]. Both of these alterations are considered founder mutations among the most homogeneous group of Ashkenazi Jews (ASH) [58,59]. It has been calculated that in the general population of the Ashkenazi Jews, the c.68_69delAG (185delAG) mutation occurs at a frequency of 1.09% [60], and the c.5266dupC (5382insC) mutation was found in 0.13% [61]. The c.5266dupC (5382insC) mutation is frequently found in Central and Eastern Europe (Poland, Lithuania, Belarus, Ukraine, Russia, Germany), where the ancestors of the almost ten million Ashkenazi Jewish population now living around the world originated [62,63]. Neuhausen et al. (1996), based on a haplotype and phenotype study of six different mutations in the BRCA1 gene in 61 families, proved that the c.5266dupC (5382insC) mutation originated in the present-day territories of the Baltic countries and spread deep into Europe and the United States with the migration of populations, particularly those with Ashkenazi roots [64].

4.1. Poland

Thanks to many years of research conducted by a group of scientists from Szczecin, it is now known that there are three founder mutations in Poland: c.5266dupC (5382insC) in exon 20, c.181T>G (300T/G) in exon 5, and c.4035delA (4153delA) in exon 11. They are responsible for up to 91% of all mutations within the BRCA1 gene [65]. Thanks to this discovery, the cost of expensive DNA testing has decreased considerably, and screening targeting only three founder mutations is now available to a broader range of breast and/or ovarian cancer (OC) patients, as well as their relatives. In 2014, three new ones were identified by Szwiec M et al., who identified recurrent mutations in BRCA1: c.3700_3704del (3819del5), c.68_69delAG (185delAG), and c.5251C>T (5370C>T) were found in multiple families, prompting the recommendation to expand the standard testing panel to include these mutations. This extended panel increased the detection rate of BRCA PVs from 5.2% to 6.7% [66].
Several large studies on the prevalence of founder mutations in the BRCA1 gene have been conducted in the general Polish population. The largest number of DNA samples from anonymous newborns from seven regions of Poland (Pomerania, Warmia and Mazury, Mazovia, Greater Poland, Lesser Poland, Lublin and Silesia) was studied by Brożek et al. [67]. The frequency of the c.5266dupC (5382insC) mutation was calculated to be 29/16,849 (0.17%) and that of the c.181T>G (300T/G) mutation to be 11/13,462 (0.08%) [67]. The third founder mutation c.4035delA (4153delA) was not investigated due to the fact that it had not been found in previous reports from these regions [68,69,70,71,72]. The authors noted statistically significant differences in the frequency of individual mutations in newborns from different regions of Poland. The c.5266dupC (5382insC) mutation was most frequently recorded in Warmia and Mazury (10/2377; 0.42%), in contrast to Pomerania (0/2578; 0.0%) (p = 0.001) and Lesser Poland (2/2231; 0.09%) (p = 0.028). The 3819delA mutation was found to be recurrent, occurring at a frequency of 4/2363 (0.17%), but only in Pomerania. In contrast, it was not found in the neighboring Warmian-Masurian province: 0/1560 [72]. The regional distribution of the most frequent BRCA1 founder mutations in Poland and neighboring countries is shown in Figure 4.
The 5382insC mutation in exon 20 of the BRCA1 gene is the most frequently described alteration in Europe (according to BIC data). Sobczak et al. [73]. were the first to describe this alteration as frequent among families burdened with breast cancer (HBC) and/or ovarian cancer (HOC, HBOC) in Poland [73]. The frequency of this mutation among families with HBC, HOC or HBOC in Poland is 34% [74], in Russia—14% [75], in Hungary—14% [76], in Slovenia—13% [77], among Ashkenazi Jewish—10% [78], in Germans—4% [79]. In contrast, it has not yet been found among Spaniards, Portuguese, Belgians, Dutch, and Scandinavians [19]. Among Russians, Belarusians, Poles, Latvians, Czechs, and Lithuanians, this mutation accounted for 94% [80], 73% [81], 60% [74], 55% [82], 37–52% [83,84], and 34% [85] of all pathogenic variants (PVs) detected in the BRCA1 gene.
The c.181T>G (300T/G) mutation in exon 5 was first recognized in 1994 in families of Polish, Russian, and German origin [86]. Since then, it has been reported in many countries, including Austria [87], Germany [79,88], Latvia [89], and other neighboring countries listed below.
Kozlowski et al. [90] and Sobczak et al. [73] were the first to identify the c.4035delA (4153delA) mutation in exon 11 in Poland [73,90]. Subsequently, this mutation was described as frequent in Russia [91], in north-western Poland [65], and in the Baltic countries, where this alteration predominates as a distinct founder effect (Table 1).

4.2. Other Countries

4.2.1. Belarus

In the general population of BC patients, the prevalence of BRCA1 gene PVs was calculated to be 4.4%. In the control group (general population), the frequency of PVs was 0.5%. Three founder mutations were identified for this particular population: c.5266dupC (5382insC) (2.5%), c.181T>G (300T/G) (1%), and c.4035delA (4153delA) (0.9%) [99]. Uglanitsa et al. (2010) [100] identified 38 of the above PVs in the BRCA1 gene among a group of 500 unselected breast cancers (7.6%). Mutations were more common in women < 50 years of age (12.6%) than in women > 50 years of age (5.6%). In the neonatal control group, the frequency was 2/251 (0.8%) [100].

4.2.2. Ukrainerus

Kitsera et al. [101] studied 335 women with breast cancer from the Western Ukraine region. However, 36 of them (10.7%) had at least a first-degree relative with breast cancer. A total of 125 affected women with an identified family history of BC were eligible for DNA testing. In 5 cases (4%), PVs in the BRCA1 gene were identified: c.5266dupC (5382insC)—2/125 (1.6%), c.68_69delAG (185delAG)—2/125 (1.6%), and c.4035delA (4153delA)—1/125 (0.8%) [101].
Similar findings were reported by Nguyen-Dumont et al. Among Ukrainian women, the prevalence of founder mutations was 13% (16 out of 123). Eleven carriers of the BRCA1 5382insC (c.5266dup) mutation, three carriers of the c.181T>G (181T>G) mutation, and two carriers of the c.68_69del (85delAG) mutation were identified. The c.4035del (4153delA) mutation was not observed in this Ukrainian cohort [92].

4.2.3. Czech Republic

Three founder mutations were found in the Czech population—c.181T>G (300T/G), c.5266dupC (5382insC), c.3700_3704del5 (3819del5)—which accounted for 52% of all detected PVs in the BRCA1 gene in the population-based study, with the most frequent mutation being c.5266dupC (5382insC) (44%) [84]. A strong Slavic founder effect was observed, especially for two mutations in the BRCA1 gene: c.181T>G (300T/G) and c.5266dupC (5382insC), which are also considered founder mutations in Poland and other Slavic countries [65].

4.2.4. Estonia

As reported by Tamboom et al. [102], c.5266dupC (5382insC) was the most common mutation in Estonia, with c.4035delA (4153delA) being the second most common [102].

4.2.5. Latvia

In Latvia, the two mutations c.5266dupC (5382insC) and c.4035delA (4153delA) account for more than 80 per cent of all BRCA1 gene alterations detected. The third—c.181T>G (300T/G)—is recurrent, but at a lower frequency. The c.4035delA (4153delA) mutation is most common among the indigenous Baltic population [82,103].

4.2.6. Lithuania

A study of PV carriage in the BRCA1 gene in Lithuania shows that there is a strong Baltic founder effect in this country, with the c.4035delA (4153delA) mutation dominating (53%), as in Latvia and Estonia, followed by the c.5266dupC (5382insC) mutation with 33% [104]. Two further mutations c.181T>G (300T/G) and c.5258G>C (5377G>C/R1753T) were also found, which together accounted for 4% of all detected lesions [85,105].

4.2.7. Germany

Eighteen PVs were detected in Germany, including the four most frequent—c.5266dupC (5382insC), c.181T>G (300T/G), c.4065_4068del4 (4184del4), and c.2338C>T (2457C>T)—which together accounted for 66% of all lesions. Mutations c.5266dupC (5382insC) and c.181T>G (300T/G) accounted for 38% [49,106].

4.2.8. Russia

In Russia, the c.5266dupC (5382insC) mutation is the vast majority (~90%). c.4035delA (4153delA), c.181T>G (300T/G) and c.68_69delAG (185delAG) are listed as the next most frequent in Western Russia [75,80,107,108].

4.2.9. Italy

Studies from Southern Italy indicate that the distribution of BRCA1 pathogenic variants is characterized by marked regional heterogeneity. Importantly, the BRCA1 c.5266dupC (5382insC) pathogenic variant has been identified in several unrelated hereditary breast and ovarian cancer families from Western Sicily, with a clear geographical clustering in areas surrounding Palermo on the northern coast and Agrigento on the southern coast of the island. This observation suggests that, beyond its well-established presence in Central and Eastern Europe, the c.5266dupC (5382insC) variant also contributes to the hereditary breast and ovarian cancer burden in selected regions of Southern Italy, likely reflecting historical migration and population admixture in the Mediterranean area. In addition to c.5266dupC (5382insC), other BRCA1 pathogenic variants have been reported in Italian populations, including region-specific founder alterations such as c.4964_4982del (5083del19), as well as less frequent recurrent variants observed sporadically across different regions of Italy, further supporting the presence of population-specific founder effects [109,110].

5. Prevalence of BRCA2 Founder Mutations

The frequency of heterozygous germline pathogenic variants (PVs) in the BRCA2 gene in the general White population is estimated to range from 1/200 to 1/700 [50,111].
Similar to certain mutations in the BRCA1 gene, specific mutations in BRCA2 may exhibit a founder effect. An example is the founder mutation 999del5 in the BRCA2 gene, which occurs in the Icelandic population with a frequency of approximately 0.4% and accounts for 8.5% of breast cancer (BC) cases [52,112]. In Finland, the mutations 9345+1G>A, c.7480C>T (C7708T), and c.8327T>G (T8555G) are specific to this population, while the mutation 8128delA is considered a founder mutation in the Bahamas [113,114]. Among one of the most genetically homogeneous groups, Ashkenazi Jews, the founder mutation in the BRCA2 gene is c.5946delT (6174delT), occurring with a frequency of 1.52% in this population [61,115].

5.1. Poland

In the Polish population, a wide variety of PVs in the BRCA2 gene has been observed. Specific recurrent BRCA2 mutations have been reported; however, their frequency in Polish families is relatively low [93]. Nevertheless, several studies have been conducted in Poland on BRCA2 gene PVs that increase the predisposition to BC.
According to the study by Cybulski et al., among 144 women with BC, 12 PVs in the BRCA2 gene were detected (8.3%). Recurrent mutations were identified in individual patients, including c.8647delC (8875delC), c.9402delC, c.9089_9090insA, c.2T>C, c.6275_6276delTT (6503delTT), c.2806_2809delAAAC (3034del4), c.5718_5719delCT, c.9246_9247insA, and c.6402_6406delTAACT (6630del5) [94].
A study conducted on a group of 1164 women with BC, recruited from two centers—Szczecin and Opole—revealed the presence of five distinct mutations in the BRCA2 gene. In the Opole center, mutations c.658_659delGT (886delGT) and c.3847_3848delGT (4075delGT) were identified, while in the Szczecin center, mutations c.5239_5240insT (5467insT), c.5946delT (6174delT), and c.7913_7917del5 (8138del5) were detected. Each of these mutations was observed in a single case [66]. The mutations detected in Szczecin were also identified as recurrent in studies conducted by Gaj et al., with frequencies of 4, 4, and 2, respectively. Overall, BRCA2 PVs were detected in 12 out of 906 individuals, representing 1.3% of the study population [95]. In a study by Balabas et al., both the c.5239_5240insT (5467insT) and c.5946delT (6174delT) mutations were each detected once among 105 individuals, 91 of whom had BC; the c.5239_5240insT (5467insT) variant was identified in a male patient [116]. The c.5946delT (6174delT) variant is a frequently occurring mutation in the Ashkenazi Jewish population [117]. Additionally, the c.9098_9099insA (9326insA) mutation, also identified in the studied population, was previously reported in the German population [106,116].
In northeastern Poland, recurrent mutations such as c.3847del (4075delG) and c.3860delA (4088delA) (the latter likely originating from Spain or Western Europe) were observed, along with newly identified mutations 7327ins/dupl19, 9068del, and 7985G>A [68,71].
A study conducted in southeastern Poland among 121 women with BC and/or OC, of whom 115 had BC, identified seven BRCA2 PVs that were present only in women with BC. The mutations c.1310_1313delAAGA (1529delA), c.9371A>T, and c.9402delC (9631delC) were each identified twice [93]. Other studies conducted in the same region of Poland also identified the c.9402del (9631del) mutation in three unrelated families among the 47 families studied with BC and/or OC from Upper Silesia, along with one occurrence of the 6886del5 mutation [118]. The c.9402del (9631del) mutation has also been reported in patients from the Czech Republic and Slovakia, suggesting it may represent a local founder variant [119,120].
In a group of 512 patients with BC and/or OC from the Warsaw Oncology Center, whose blood samples were collected between 2003 and 2010, Kluska et al. identified a total of 52 (10%) PVs in the BRCA1/2 genes. The mutations c.7251_7252delCA (7477delCA) and c.9118-2A>G (IVS23-2A>G) were each detected in three patients, while the c.9371A>T (N3124I) mutation, classified as a variant of uncertain significance (VUS), was identified in six patients. The remaining pathogenic mutations were found as single occurrences [96].
Studies conducted on a group of 2466 women with early-onset BC revealed that BRCA2 PVs were rare in this population, occurring in only 0.08% of patients diagnosed with BC at age 40 or younger. Only two individual BRCA2 mutations were identified: c.3847_3848delGT (4065delGT) and c.658_659delGT (680delGT) [97] (Table 2).

5.2. Other Countries

5.2.1. Belarus

Reports on BRCA2 mutations in Belarus are limited, which means that our understanding of the full spectrum of these mutations remains incomplete. In a study involving 340 patients with hereditary breast and ovarian cancer (HBOC), pathogenic variants in the BRCA1/2 genes were found in 98 patients (29%). Among the Belarusian population, the founder of the BRCA2 c.658_659delGT (886delGT) mutation was identified in three cases [124].

5.2.2. Russia

Data on BRCA2 mutations in Russia is limited. In Russia, the vast majority of BRCA2 mutations consist of the Ashkenazi variant c.5964delT (6174delT), which may be due to the long-standing presence of the Jewish community in Russia and its high level of integration with the native population [108].

5.2.3. Lithuania

In the Lithuanian population, BRCA2 mutations are less common compared to BRCA1 mutations, but their presence is significant in the context of HBOC risk. The most frequently occurring founder mutation in the BRCA2 gene in this population is c.658_659del (886delGT), which accounts for half of all BRCA2 mutations and 5% of all BRCA1 and BRCA2 mutations combined. This mutation is likely associated with a founder effect, as it has not been widely reported in other populations, suggesting its specificity to this region [105].

5.2.4. Czech Republic

In studies conducted among Czech patients at high risk or suffering from BC and/or OC, a founder effect was observed for two BRCA2 mutations—c.7913_7917del5 (8138del5) and c.8537_8538del2—which have only been reported in Canada and the USA [84,125]. These mutations accounted for 15.6% and 16.7% of all identified BRCA2 mutations, respectively. Additionally, Foretova et al. demonstrated in their research that another common BRCA2 mutation, c.7910_7914del5, represented 26% of the identified BRCA2 PVs [119].

5.2.5. Germany

In Germany, 13 recurrent BRCA2 PVs were identified, accounting for 44% of all mutations in this gene. Seven of these mutations, representing 28% of all identified mutations, occurred at least three times. The most common mutations showing a likely founder effect include: c.1813dupA (2041insA), c.4478del4 (4706del4), and c.9098dupA (9326insA) [106].

5.2.6. Ukraine, Estonia, Latvia

Currently, there is no compelling data on BRCA2 founder mutations in these populations.

6. Genetic Counseling

Genetic counseling for breast cancer (BC) has become increasingly important with advances in genetic testing and understanding of hereditary cancer syndromes. This counseling helps identify individuals at high risk for BC based on the family history and genetic composition, providing them with personalized risk management strategies and informed decision-making tools [126].

6.1. Impact of Genetic Counseling

Genetic counseling and testing enable the development of tailored risk management strategies. High-risk individuals may benefit from increased surveillance, including more frequent mammograms and MRI scans, and preventive options such as prophylactic mastectomy and oophorectomy. For those already diagnosed with BC, genetic testing can inform treatment decisions. For instance, BRCA1/2 pathogenic variant (PV) carriers may be eligible for PARP inhibitors, which have shown efficacy in treating certain types of BC. Genetic counseling also extends to family members. Identifying a pathogenic variant in an individual can prompt testing and preventive measures for relatives, potentially reducing the overall familial cancer burden [47,126].

6.2. Challenges and Future Directions

Despite the benefits, there are challenges in genetic counseling for BC. These include disparities in access to genetic services, particularly in underserved populations, as well as the need for a greater number of trained genetic counselors. Furthermore, the interpretation of variants of unknown significance (VUS) remains complex and can lead to uncertainties in clinical management. Advancements in technology, such as next-generation sequencing, have made multigene panel testing more accessible and comprehensive. However, this also increases the likelihood of detecting VUS, necessitating ongoing research and updated guidelines to manage these findings effectively.
In the future, integrating genetic counseling into routine oncology practice and conducting longitudinal studies to understand the long-term outcomes of genetic testing will be crucial. These efforts will help ensure that all individuals at risk for hereditary BC receive the benefits of genetic counseling and testing [21].

7. Conclusions

The findings presented in this study highlight the significant role of founder mutations in the BRCA1 and BRCA2 genes in hereditary breast cancer (HBC), particularly within the Polish population. The identification of specific recurrent mutations, such as 5382insC, 300T/G, and 4153delA, underscores the importance of tailored genetic testing strategies to improve diagnostic efficiency and accessibility. Comparative analysis with other populations demonstrates the impact of geographical and ethnic factors on PV prevalence, emphasizing the need for population-specific screening protocols.
Additionally, the integration of genetic counseling into cancer management plays a critical role in risk assessment, treatment planning, and preventive measures for individuals and families affected by hereditary BC. Future research should focus on expanding the understanding of genetic variants, addressing challenges in the interpretation of variants of uncertain significance, and promoting equitable access to genetic services. These efforts will enhance the early detection and management of hereditary BC, ultimately reducing its burden on affected populations.

Author Contributions

B.K.: conceptualized the review, performed the literature analysis, and wrote the original draft of the manuscript. B.P. and R.P.: reviewed, edited, and supervised the work. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Data Availability Statement

No new data were created or analyzed in this study.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
BCBreast cancer
OCOvarian cancer
HBCHereditary breast cancer
FHSFamily History Score
PVsPathogenic variants
RRRelative risk
BICBreast Cancer Information Core
ASHAshkenazi Jews
HOCHereditary ovarian cancer
HBOCHereditary breast and ovarian cancer
VUSVariant of uncertain significance

References

  1. Cancer (IARC). Global Cancer Observatory. Available online: https://gco.iarc.fr/ (accessed on 10 September 2024).
  2. Available online: https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html (accessed on 10 September 2024).
  3. World Health Organization (WHO). Available online: https://www.who.int (accessed on 11 September 2024).
  4. Krajowy Rejestr Nowotworów. Available online: http://onkologia.org.pl/pl/raporty (accessed on 11 September 2024).
  5. Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: Individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 2012, 13, 1141–1151. [Google Scholar] [CrossRef] [PubMed]
  6. Sisti, J.S.; Bernstein, J.L.; Lynch, C.F.; Reiner, A.S.; Mellemkjaer, L.; Brooks, J.D.; Knight, J.A.; Bernstein, L.; Malone, K.E.; Woods, M.; et al. Reproductive factors, tumor estrogen receptor status and contralateral breast cancer risk: Results from the WECARE study. SpringerPlus 2015, 4, 825. [Google Scholar] [CrossRef]
  7. Rana, M.S.; Rahman, M.M.; Baker, J.; Houssami, N.; Yu, X.Q.; Marinovich, M.L. Association of lifestyle factors with breast cancer incidence: An overview of systematic reviews. Chin. J. Cancer Res. 2025, 37, 575–591. [Google Scholar] [CrossRef]
  8. Zare, N.; Haem, E.; Lankarani, K.B.; Heydari, S.T.; Barooti, E. Breast cancer risk factors in a defined population: Weighted logistic regression approach for rare events. J. Breast Cancer 2013, 16, 214–219. [Google Scholar] [CrossRef]
  9. Catsburg, C.; Miller, A.B.; Rohan, T.E. Active cigarette smoking and risk of breast cancer. Int. J. Cancer 2015, 136, 2204–2209. [Google Scholar] [CrossRef]
  10. Rumgay, H.; Shield, K.; Charvat, H.; Ferrari, P.; Sornpaisarn, B.; Obot, I.; Islami, F.; Lemmens, V.E.P.P.; Rehm, J.; Soerjomataram, I. Global burden of cancer in 2020 attributable to alcohol consumption: A population-based study. Lancet Oncol. 2021, 22, 1071–1080. [Google Scholar] [CrossRef]
  11. Honrado, E.; Benítez, J.; Palacios, J. The molecular pathology of hereditary breast cancer: Genetic testing and therapeutic implications. Mod. Pathol. 2005, 18, 1305–1320. [Google Scholar] [CrossRef]
  12. Liaw, D.; Marsh, D.J.; Li, J.; Dahia, P.L.M.; Wang, S.I.; Zheng, Z.; Bose, S.; Call, K.M.; Tsou, H.C.; Peacocke, M.; et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 1997, 16, 64–67. [Google Scholar] [CrossRef]
  13. Li, J.; Yen, C.; Liaw, D.; Podsypanina, K.; Bose, S.; Wang, S.I.; Puc, J.; Miliaresis, C.; Rodgers, L.; McCombie, R.; et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275, 1943–1947. [Google Scholar] [CrossRef] [PubMed]
  14. Greenblatt, M.S.; Chappuis, P.O.; Bond, J.P.; Hamel, N.; Foulkes, W.D. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: Distinctive spectrum and structural distribution. Cancer Res. 2001, 61, 4092–4097. [Google Scholar] [PubMed]
  15. Vahteristo, P.; Bartkova, J.; Eerola, H.; Syrjäkoski, K.; Ojala, S.; Kilpivaara, O.; Tamminen, A.; Kononen, J.; Aittomäki, K.; Heikkilä, P.; et al. A CHEK2 Genetic Variant Contributing to a Substantial Fraction of Familial Breast Cancer. Am. J. Hum. Genet. 2002, 71, 432–438. [Google Scholar] [CrossRef]
  16. Thompson, D.; Duedal, S.; Kirner, J.; McGuffog, L.; Last, J.; Reiman, A.; Byrd, P.; Taylor, M.; Easton, D.F. Cancer risks and mortality in heterozygous ATM mutation carriers. J. Natl. Cancer Inst. 2005, 97, 813–822. [Google Scholar] [CrossRef] [PubMed]
  17. Rahman, N.; Seal, S.; Thompson, D.; Kelly, P.; Renwick, A.; Elliott, A.; Reid, S.; Spanova, K.; Barfoot, R.; Chagtai, T.; et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat. Genet. 2007, 39, 165–167. [Google Scholar] [CrossRef]
  18. Fackenthal, J.D.; Olopade, O.I. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat. Rev. Cancer 2007, 7, 937–948. [Google Scholar] [CrossRef] [PubMed]
  19. Ferla, R.; Calò, V.; Cascio, S.; Rinaldi, G.; Badalamenti, G.; Carreca, I.; Surmacz, E.; Colucci, G.; Bazan, V.; Russo, A. Founder mutations in BRCA1 and BRCA2 genes. Ann. Oncol. 2007, 18, vi93–vi98. [Google Scholar] [CrossRef]
  20. Janavičius, R. Founder BRCA1/2 mutations in the Europe: Implications for hereditary breast-ovarian cancer prevention and control. EPMA J. 2010, 1, 397–412. [Google Scholar] [CrossRef] [PubMed]
  21. Pensabene, M.; Calabrese, A.; von Arx, C.; Caputo, R.; De Laurentiis, M. Cancer genetic counselling for hereditary breast cancer in the era of precision oncology. Cancer Treat. Rev. 2024, 125, 102702. [Google Scholar] [CrossRef]
  22. Roseman, D.L.; Straus, A.K.; Shorey, W. A positive family history of breast cancer: Does it effect diminish with age? Arch. Intern. Med. 1990, 150, 191–194. [Google Scholar] [CrossRef]
  23. Mukama, T.; Kharazmi, E.; Sundquist, K.; Sundquist, J.; Brenner, H.; Fallah, M. Familial risk of breast cancer by dynamic, accumulative, and static definitions of family history. Cancer 2020, 126, 2837–2848. [Google Scholar] [CrossRef]
  24. Brewer, H.R.; Jones, M.E.; Schoemaker, M.J.; Ashworth, A.; Swerdlow, A.J. Family history and risk of breast cancer: An analysis accounting for family structure. Breast Cancer Res. Treat. 2017, 165, 193–200. [Google Scholar] [CrossRef]
  25. Broca, P. Traité des Tumeurs: I. P.; Asselin: Thouars, France, 1866. [Google Scholar]
  26. Miki, Y.; Swensen, J.; Shattuck-Eidens, D.; Futreal, P.A.; Harshman, K.; Tavtigian, S.; Liu, Q.; Cochran, C.; Bennett, L.M.; Ding, W.; et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266, 66–71. [Google Scholar] [CrossRef]
  27. Wooster, R.; Bignell, G.; Lancaster, J.; Swift, S.; Seal, S.; Mangion, J.; Collins, N.; Gregory, S.; Gumbs, C.; Micklem, G. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995, 378, 789–792. [Google Scholar] [CrossRef]
  28. Couch, F.J.; Shimelis, H.; Hu, C.; Hart, S.N.; Polley, E.C.; Na, J.; Hallberg, E.; Moore, R.; Thomas, A.; Lilyquist, J.; et al. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. JAMA Oncol. 2017, 3, 1190–1196. [Google Scholar] [CrossRef]
  29. Mouchawar, J.; Korch, C.; Byers, T.; Pitts, T.M.; Li, E.; McCredie, M.R.E.; Giles, G.G.; Hopper, J.L.; Southey, M.C. Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study. Cancer Res. 2010, 70, 4795–4800. [Google Scholar] [CrossRef]
  30. Antoniou, A.C.; Casadei, S.; Heikkinen, T.; Barrowdale, D.; Pylkäs, K.; Roberts, J.; Lee, A.; Subramanian, D.; De Leeneer, K.; Fostira, F.; et al. Breast-cancer risk in families with mutations in PALB2. N. Engl. J. Med. 2014, 371, 497–506. [Google Scholar] [CrossRef]
  31. Damiola, F.; Pertesi, M.; Oliver, J.; Le Calvez-Kelm, F.; Voegele, C.; Young, E.L.; Robinot, N.; Forey, N.; Durand, G.; Vallée, M.P.; et al. Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: Results from a Breast Cancer Family Registry case-control mutation-screening study. Breast Cancer Res. 2014, 16, R58. [Google Scholar] [CrossRef] [PubMed]
  32. Villarreal-Garza, C.; Weitzel, J.N.; Llacuachaqui, M.; Sifuentes, E.; Magallanes-Hoyos, M.C.; Gallardo, L.; Alvarez-Gómez, R.M.; Herzog, J.; Castillo, D.; Royer, R.; et al. The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer. Breast Cancer Res. Treat. 2015, 150, 389–394. [Google Scholar] [CrossRef] [PubMed]
  33. Lin, P.-H.; Kuo, W.-H.; Huang, A.-C.; Lu, Y.-S.; Lin, C.-H.; Kuo, S.-H.; Wang, M.-Y.; Liu, C.-Y.; Cheng, F.-T.; Yeh, M.-H.; et al. Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer. Oncotarget 2016, 7, 8310–8320. [Google Scholar] [CrossRef] [PubMed]
  34. Chodosh, L.A. Expression of BRCA1 and BRCA2 in normal and neoplastic cells. J. Mammary Gland. Biol. Neoplasia 1998, 3, 389–402. [Google Scholar] [CrossRef]
  35. Varol, U.; Kucukzeybek, Y.; Alacacioglu, A.; Somali, I.; Altun, Z.; Aktas, S.; Oktay Tarhan, M. BRCA genes: BRCA 1 and BRCA 2. JBUON 2018, 23, 862–866. [Google Scholar]
  36. Wooster, R.; Neuhausen, S.L.; Mangion, J.; Quirk, Y.; Ford, D.; Collins, N.; Nguyen, K.; Seal, S.; Tran, T.; Averill, D.; et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994, 265, 2088–2090. [Google Scholar] [CrossRef]
  37. Narod, S.A.; Foulkes, W.D. BRCA1 and BRCA2: 1994 and beyond. Nat. Rev. Cancer 2004, 4, 665–676. [Google Scholar] [CrossRef]
  38. Yoshida, K.; Miki, Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci. 2004, 95, 866–871. [Google Scholar] [CrossRef]
  39. Takaoka, M.; Miki, Y. BRCA1 gene: Function and deficiency. Int. J. Clin. Oncol. 2018, 23, 36–44. [Google Scholar] [CrossRef] [PubMed]
  40. Kleiblova, P.; Stolarova, L.; Krizova, K.; Lhota, F.; Hojny, J.; Zemankova, P.; Havranek, O.; Vocka, M.; Cerna, M.; Lhotova, K.; et al. Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer. Int. J. Cancer 2019, 145, 1782–1797. [Google Scholar] [CrossRef]
  41. Ford, D.; Easton, D.F.; Bishop, D.T.; Narod, S.A.; Goldgar, D.E. Risks of cancer in BRCA1-mutation carriers. Lancet 1994, 343, 692–695. [Google Scholar] [CrossRef]
  42. Antoniou, A.; Pharoah, P.D.; Narod, S.; Risch, H.A.; Eyfjord, J.E.; Hopper, J.L.; Loman, N.; Olsson, H.; Johannsson, O.; Borg, A.; et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: A combined analysis of 22 studies. Am. J. Hum. Genet. 2003, 72, 1117–1130. [Google Scholar] [CrossRef]
  43. Li, S.; Silvestri, V.; Leslie, G.; Rebbeck, T.R.; Neuhausen, S.L.; Hopper, J.L.; Nielsen, H.R.; Lee, A.; Yang, X.; McGuffog, L.; et al. Cancer Risks Associated with BRCA1 and BRCA2 Pathogenic Variants. J. Clin. Oncol. 2022, 40, 1529–1541. [Google Scholar] [CrossRef] [PubMed]
  44. Goggins, M.; Schutte, M.; Lu, J.; Moskaluk, C.A.; Weinstein, C.L.; Petersen, G.M.; Yeo, C.J.; Jackson, C.E.; Lynch, H.T.; Hruban, R.H.; et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 1996, 56, 5360–5364. [Google Scholar]
  45. Friedenson, B. BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. Medscape Gen. Med. 2005, 7, 60. [Google Scholar]
  46. Nyberg, T.; Frost, D.; Barrowdale, D.; Evans, D.G.; Bancroft, E.; Adlard, J.; Ahmed, M.; Barwell, J.; Brady, A.F.; Brewer, C.; et al. Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study. Eur. Urol. 2020, 77, 24–35. [Google Scholar] [CrossRef] [PubMed]
  47. Daly, M.B.; Pal, T.; Berry, M.P.; Buys, S.S.; Dickson, P.; Domchek, S.M.; Elkhanany, A.; Friedman, S.; Goggins, M.; Hutton, M.L.; et al. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. 2021, 19, 77–102. [Google Scholar] [CrossRef] [PubMed]
  48. Kuchenbaecker, K.B.; Hopper, J.L.; Barnes, D.R.; Phillips, K.-A.; Mooij, T.M.; Roos-Blom, M.-J.; Jervis, S.; van Leeuwen, F.E.; Milne, R.L.; Andrieu, N.; et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA 2017, 317, 2402–2416. [Google Scholar] [CrossRef]
  49. Mann, G.J.; Thorne, H.; Balleine, R.L.; Butow, P.N.; Clarke, C.L.; Edkins, E.; Evans, G.M.; Fereday, S.; Haan, E.; Gattas, M.; et al. Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Breast Cancer Res. 2006, 8, R12. [Google Scholar] [CrossRef]
  50. Antoniou, A.C.; Pharoah, P.D.P.; McMullan, G.; Day, N.E.; Stratton, M.R.; Peto, J.; Ponder, B.J.; Easton, D.F. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br. J. Cancer 2002, 86, 76–83. [Google Scholar] [CrossRef]
  51. National Human Genome Research Institute (NHGRI). Online Research Resources. Available online: https://research.nhgri.nih.gov/ (accessed on 24 October 2024).
  52. Johannesdottir, G.; Gudmundsson, J.; Bergthorsson, J.T.; Arason, A.; Agnarsson, B.A.; Eiriksdottir, G.; Johannsson, O.T.; Borg, A.; Ingvarsson, S.; Easton, D.F.; et al. High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients. Cancer Res. 1996, 56, 3663–3665. [Google Scholar]
  53. Trottier, M.; Lunn, J.; Butler, R.; Curling, D.; Turnquest, T.; Francis, W.; Halliday, D.; Royer, R.; Zhang, S.; Li, S.; et al. Prevalence of founder mutations in the BRCA1 and BRCA2 genes among unaffected women from the Bahamas. Clin. Genet. 2016, 89, 328–331. [Google Scholar] [CrossRef]
  54. Vézina, H.; Durocher, F.; Dumont, M.; Houde, L.; Szabo, C.; Tranchant, M.; Chiquette, J.; Plante, M.; Laframboise, R.; Lépine, J.; et al. Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families. Hum. Genet. 2005, 117, 119–132. [Google Scholar] [CrossRef]
  55. Petrij-Bosch, A.; Peelen, T.; van Vliet, M.; van Eijk, R.; Olmer, R.; Drüsedau, M.; Hogervorst, F.B.; Hageman, S.; Arts, P.J.; Ligtenberg, M.J.; et al. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat. Genet. 1997, 17, 341–345. [Google Scholar] [CrossRef]
  56. Johannsson, O.; Ostermeyer, E.A.; Håkansson, S.; Friedman, L.S.; Johansson, U.; Sellberg, G.; Brøndum-Nielsen, K.; Sele, V.; Olsson, H.; King, M.C.; et al. Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden. Am. J. Hum. Genet. 1996, 58, 441–450. [Google Scholar] [PubMed]
  57. Andersen, T.I.; Børresen, A.L.; Møller, P. A common BRCA1 mutation in Norwegian breast and ovarian cancer families? Am. J. Hum. Genet. 1996, 59, 486–487. [Google Scholar]
  58. Levy-Lahad, E.; Catane, R.; Eisenberg, S.; Kaufman, B.; Hornreich, G.; Lishinsky, E.; Shohat, M.; Weber, B.L.; Beller, U.; Lahad, A.; et al. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: Frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am. J. Hum. Genet. 1997, 60, 1059–1067. [Google Scholar]
  59. Risch, H.A.; McLaughlin, J.R.; Cole, D.E.; Rosen, B.; Bradley, L.; Kwan, E.; Jack, E.; Vesprini, D.J.; Kuperstein, G.; Abrahamson, J.L.; et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am. J. Hum. Genet. 2001, 68, 700–710. [Google Scholar] [CrossRef]
  60. Struewing, J.P.; Abeliovich, D.; Peretz, T.; Avishai, N.; Kaback, M.M.; Collins, F.S.; Brody, L.C. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat. Genet. 1995, 11, 198–200. [Google Scholar] [CrossRef] [PubMed]
  61. Roa, B.B.; Boyd, A.A.; Volcik, K.; Richards, C.S. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat. Genet. 1996, 14, 185–187. [Google Scholar] [CrossRef] [PubMed]
  62. Phelan, C.M.; Kwan, E.; Jack, E.; Li, S.; Morgan, C.; Aubé, J.; Hanna, D.; Narod, S.A. A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families. Hum. Mutat. 2002, 20, 352–357. [Google Scholar] [CrossRef] [PubMed]
  63. Antoniou, A.C.; Pharoah, P.D.P.; Narod, S.; Risch, H.A.; Eyfjord, J.E.; Hopper, J.L.; Olsson, H.; Johannsson, O.; Borg, A.; Pasini, B.; et al. Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: A combined analysis of 22 population based studies. J. Med. Genet. 2005, 42, 602–603. [Google Scholar] [CrossRef]
  64. Neuhausen, S.L.; Mazoyer, S.; Friedman, L.; Stratton, M.; Offit, K.; Caligo, A.; Tomlinson, G.; Cannon-Albright, L.; Bishop, T.; Kelsell, D.; et al. Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: Results of an international study. Am. J. Hum. Genet. 1996, 58, 271–280. [Google Scholar]
  65. Górski, B.; Byrski, T.; Huzarski, T.; Jakubowska, A.; Menkiszak, J.; Gronwald, J.; Pluzańska, A.; Bebenek, M.; Fischer-Maliszewska, L.; Grzybowska, E.; et al. Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am. J. Hum. Genet. 2000, 66, 1963–1968. [Google Scholar] [CrossRef]
  66. Szwiec, M.; Jakubowska, A.; Górski, B.; Huzarski, T.; Tomiczek-Szwiec, J.; Gronwald, J.; Dębniak, T.; Byrski, T.; Kluźniak, W.; Wokołorczyk, D.; et al. Recurrent mutations of BRCA1 and BRCA2 in Poland: An update. Clin. Genet. 2015, 87, 288–292. [Google Scholar] [CrossRef]
  67. Brozek, I.; Cybulska, C.; Ratajska, M.; Piatkowska, M.; Kluska, A.; Balabas, A.; Dabrowska, M.; Nowakowska, D.; Niwinska, A.; Pamula-Pilat, J.; et al. Prevalence of the most frequent BRCA1 mutations in Polish population. J. Appl. Genet. 2011, 52, 325–330. [Google Scholar] [CrossRef]
  68. van Der Looij, M.; Wysocka, B.; Brozek, I.; Jassem, J.; Limon, J.; Olah, E. Founder BRCA1 mutations and two novel germline BRCA2 mutations in breast and/or ovarian cancer families from North-Eastern Poland. Hum. Mutat. 2000, 15, 480–481. [Google Scholar] [CrossRef]
  69. Grzybowska, E.; Siemińska, M.; Zientek, H.; Kalinowska, E.; Michalska, J.; Utracka-Hutka, B.; Rogozińska-Szczepka, J.; Kaźmierczak-Maciejewska, M. Germline mutations in the BRCA1 gene predisposing to breast and ovarian cancers in Upper Silesia population. Acta Biochim. Pol. 2002, 49, 351–356. [Google Scholar] [CrossRef]
  70. Paszko, Z.; Skasko, E.; Wiśniewska, A.; Konopka, B.; Niwińska, A.; Pieńkowski, T. Changes in BRCA1 gene in patients with familial breast cancer in the Warsaw region of Poland. Nowotw. J. Oncol. 2002, 42, 97–103. [Google Scholar]
  71. Perkowska, M.; BroZek, I.; Wysocka, B.; Haraldsson, K.; Sandberg, T.; Johansson, U.; Sellberg, G.; Borg, A.; Limon, J. BRCA1 and BRCA2 mutation analysis in breast-ovarian cancer families from northeastern Poland. Hum. Mutat. 2003, 21, 553–554. [Google Scholar] [CrossRef]
  72. Ratajska, M.; Brozek, I.; Senkus-Konefka, E.; Jassem, J.; Stepnowska, M.; Palomba, G.; Pisano, M.; Casula, M.; Palmieri, G.; Borg, A.; et al. BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in Northern Poland. Oncol. Rep. 2008, 19, 263–268. [Google Scholar] [CrossRef] [PubMed]
  73. Sobczak, K.; Kozłowski, P.; Napierała, M.; Czarny, J.; Woźniak, M.; Kapuścińska, M.; Łośko, M.; Koziczak, M.; Jasińska, A.; Powierska, J.; et al. Novel BRCA1 mutations and more frequent intron-20 alteration found among 236 women from Western Poland. Oncogene 1997, 15, 1773–1779. [Google Scholar] [CrossRef] [PubMed]
  74. Górski, B.; Jakubowska, A.; Huzarski, T.; Byrski, T.; Gronwald, J.; Grzybowska, E.; Mackiewicz, A.; Stawicka, M.; Bebenek, M.; Sorokin, D.; et al. A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int. J. Cancer 2004, 110, 683–686. [Google Scholar] [CrossRef]
  75. Sokolenko, A.P.; Mitiushkina, N.V.; Buslov, K.G.; Bit-Sava, E.M.; Iyevleva, A.G.; Chekmariova, E.V.; Kuligina, E.S.; Ulibina, Y.M.; Rozanov, M.E.; Suspitsin, E.N.; et al. High frequency of BRCA1 5382insC mutation in Russian breast cancer patients. Eur. J. Cancer 2006, 42, 1380–1384. [Google Scholar] [CrossRef]
  76. Ramus, S.J.; Kote-Jarai, Z.; Friedman, L.S.; van der Looij, M.; Gayther, S.A.; Csokay, B.; Ponder, B.A.; Olah, E. Analysis of BRCA1 and BRCA2 mutations in Hungarian families with breast or breast-ovarian cancer. Am. J. Hum. Genet. 1997, 60, 1242–1246. [Google Scholar] [PubMed]
  77. Krajc, M.; Teugels, E.; Zgajnar, J.; Goelen, G.; Besic, N.; Novakovic, S.; Hocevar, M.; De Grève, J. Five recurrent BRCA1/2 mutations are responsible for cancer predisposition in the majority of Slovenian breast cancer families. BMC Med. Genet. 2008, 9, 83. [Google Scholar] [CrossRef]
  78. Couch, F.J.; Weber, B.L. Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Hum. Mutat. 1996, 8, 8–18. [Google Scholar] [CrossRef]
  79. Backe, J.; Hofferbert, S.; Skawran, B.; Dörk, T.; Stuhrmann, M.; Karstens, J.H.; Untch, M.; Meindl, A.; Burgemeister, R.; Chang-Claude, J.; et al. Frequency of BRCA1 mutation 5382insC in German breast cancer patients. Gynecol. Oncol. 1999, 72, 402–406. [Google Scholar] [CrossRef]
  80. Loginova, A.N.; Pospekhova, N.I.; Lyubchenko, L.N.; Budilov, A.V.; Zakhar’ev, V.M.; Gar’kavtseva, R.F.; Ginter, E.K.; Karpukhin, A.V. Spectrum of mutations in BRCA1 gene in hereditary forms of breast and ovarian cancer in Russian families. Bull. Exp. Biol. Med. 2003, 136, 276–278. [Google Scholar] [CrossRef]
  81. Oszurek, O.; Gorski, B.; Gronwald, J.; Prosolow, Z.; Uglanica, K.; Murinow, A.; Bobko, I.; Downar, O.; Zlobicz, M.; Norik, D.; et al. Founder mutations in the BRCA1 gene in west Belarusian breast-ovarian cancer families. Clin. Genet. 2001, 60, 470–471. [Google Scholar] [CrossRef]
  82. Tikhomirova, L.; Sinicka, O.; Smite, D.; Eglitis, J.; Hodgson, S.V.; Stengrevics, A. High prevalence of two BRCA1 mutations, 4154delA and 5382insC, in Latvia. Fam. Cancer 2005, 4, 77–84. [Google Scholar] [CrossRef] [PubMed]
  83. Pohlreich, P.; Zikan, M.; Stribrna, J.; Kleibl, Z.; Janatova, M.; Kotlas, J.; Zidovska, J.; Novotny, J.; Petruzelka, L.; Szabo, C.; et al. High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area. Breast Cancer Res. 2005, 7, R728. [Google Scholar] [CrossRef] [PubMed]
  84. Machackova, E.; Foretova, L.; Lukesova, M.; Vasickova, P.; Navratilova, M.; Coene, I.; Pavlu, H.; Kosinova, V.; Kuklova, J.; Claes, K. Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer. BMC Cancer 2008, 8, 140. [Google Scholar] [CrossRef]
  85. Janavicius, R.; Pepalyte, I.; Kucinskas, V. Novel and common BRCA1 mutations in familial breast/ovarian cancer patients from Lithuania. Breast Cancer Res. Treat. 2009, 117, 467–469. [Google Scholar] [CrossRef] [PubMed]
  86. Friedman, L.S.; Ostermeyer, E.A.; Szabo, C.I.; Dowd, P.; Lynch, E.D.; Rowell, S.E.; King, M.C. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat. Genet. 1994, 8, 399–404. [Google Scholar] [CrossRef]
  87. Wagner, T.M.; Möslinger, R.A.; Muhr, D.; Langbauer, G.; Hirtenlehner, K.; Concin, H.; Doeller, W.; Haid, A.; Lang, A.H.; Mayer, P.; et al. BRCA1-related breast cancer in Austrian breast and ovarian cancer families: Specific BRCA1 mutations and pathological characteristics. Int. J. Cancer 1998, 77, 354–360. [Google Scholar] [CrossRef]
  88. Hamann, U.; Brauch, H.; Garvin, A.M.; Bastert, G.; Scott, R.J. German family study on hereditary breast and/or ovarian cancer: Germline mutation analysis of the BRCA1 gene. Genes Chromosomes Cancer 1997, 18, 126–132. [Google Scholar] [CrossRef]
  89. Csokay, B.; Tihomirova, L.; Stengrevics, A.; Sinicka, O.; Olah, E. Strong founder effects in BRCA1 mutation carrier breast cancer patients from Latvia. Hum. Mutat. 1999, 14, 92. [Google Scholar] [CrossRef]
  90. Kozłowski, P.; Sobczak, K.; Napierała, M.; Woźniak, M.; Czarny, J.; Włodzimierz, J.; Kryzosiak, J. PCR-SSCP-HDX analysis of pooled DNA for more rapid detection of germline mutations in large genes. The BRCA1 example. Nucleic Acids Res. 1996, 24, 1177–1178. [Google Scholar] [CrossRef] [PubMed]
  91. Gayther, S.A.; Harrington, P.; Russell, P.; Kharkevich, G.; Garkavtseva, R.F.; Ponder, B.A. Frequently occurring germ-line mutations of the BRCA1 gene in ovarian cancer families from Russia. Am. J. Hum. Genet. 1997, 60, 1239–1242. [Google Scholar] [PubMed]
  92. Nguyen-Dumont, T.; Karpinski, P.; Sasiadek, M.M.; Akopyan, H.; Steen, J.A.; Theys, D.; Hammet, F.; Tsimiklis, H.; Park, D.J.; Pope, B.J.; et al. Genetic testing in Poland and Ukraine: Should comprehensive germline testing of BRCA1 and BRCA2 be recommended for women with breast and ovarian cancer? Genet. Res. 2020, 102, e6. [Google Scholar] [CrossRef] [PubMed]
  93. Wojcik, P.; Jasiowka, M.; Strycharz, E.; Sobol, M.; Hodorowicz-Zaniewska, D.; Skotnicki, P.; Byrski, T.; Blecharz, P.; Marczyk, E.; Cedrych, I.; et al. Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland. Hered. Cancer Clin. Pract. 2016, 14, 5. [Google Scholar] [CrossRef]
  94. Cybulski, C.; Lubiński, J.; Wokołorczyk, D.; Kuźniak, W.; Kashyap, A.; Sopik, V.; Huzarski, T.; Gronwald, J.; Byrski, T.; Szwiec, M.; et al. Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland. Clin. Genet. 2015, 88, 366–370. [Google Scholar] [CrossRef]
  95. Gaj, P.; Kluska, A.; Nowakowska, D.; Bałabas, A.; Piątkowska, M.; Dabrowska, M.; Niwińska, A.; Ostrowski, J. High frequency of BRCA1 founder mutations in Polish women with nonfamilial breast cancer. Fam. Cancer 2012, 11, 623–628. [Google Scholar] [CrossRef]
  96. Kluska, A.; Balabas, A.; Paziewska, A.; Kulecka, M.; Nowakowska, D.; Mikula, M.; Ostrowski, J. New recurrent BRCA1/2 mutations in Polish patients with familial breast/ovarian cancer detected by next generation sequencing. BMC Med. Genom. 2015, 8, 19. [Google Scholar] [CrossRef]
  97. Rogoża-Janiszewska, E.; Malińska, K.; Cybulski, C.; Jakubowska, A.; Gronwald, J.; Huzarski, T.; Lener, M.; Górski, B.; Kluźniak, W.; Rudnicka, H.; et al. Prevalence of Recurrent Mutations Predisposing to Breast Cancer in Early-Onset Breast Cancer Patients from Poland. Cancers 2020, 12, 2321. [Google Scholar] [CrossRef] [PubMed]
  98. Lubiński, J.; Górski, B.; Huzarski, T.; Byrski, T.; Gronwald, J.; Serrano-Fernández, P.; Domagała, W.; Chosia, M.; Uciński, M.; Grzybowska, E.; et al. BRCA1-positive breast cancers in young women from Poland. Breast Cancer Res. Treat. 2006, 99, 71–76. [Google Scholar] [CrossRef]
  99. Bogdanova, N.V.; Antonenkova, N.N.; Rogov, Y.I.; Karstens, J.H.; Hillemanns, P.; Dörk, T. High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus. Clin. Genet. 2010, 78, 364–372. [Google Scholar] [CrossRef]
  100. Uglanitsa, N.; Oszurek, O.; Uglanitsa, K.; Savonievich, E.; Lubiński, J.; Cybulski, C.; Debniak, T.; Narod, S.; Gronwald, J. The contribution of founder mutations in BRCA1 to breast cancer in Belarus. Clin. Genet. 2010, 78, 377–380. [Google Scholar] [CrossRef] [PubMed]
  101. Kitsera, N.; Shparyk, Y.; Bilynsky, B.; Duda, I.; Kachmar, T.; Oleksyak, O. BRCA1 4153delA mutation (“Baltic/Black Sea”) in breast cancer patients in Ukraine. Nowotw. J. Oncol. 2014, 64, 246–250. [Google Scholar] [CrossRef]
  102. Tamboom, K.; Kaasik, K.; Aršavskaja, J.; Tekkel, M.; Lilleorg, A.; Padrik, P.; Metspalu, A.; Veidebaum, T. BRCA1 mutations in women with familial or early-onset breast cancer and BRCA2 mutations in familial cancer in Estonia. Hered. Cancer Clin. Pract. 2010, 8, 4. [Google Scholar] [CrossRef] [PubMed]
  103. Ozolina, S.; Sinicka, O.; Jankevics, E.; Inashkina, I.; Lubinski, J.; Gorski, B.; Gronwald, J.; Nasedkina, T.; Fedorova, O.; Lyubchenko, L.; et al. The 4154delA mutation carriers in the BRCA1 gene share a common ancestry. Fam. Cancer 2009, 8, 1–4. [Google Scholar] [CrossRef]
  104. Gronwald, J.; Elsakov, P.; Górski, B.; Lubiński, J. High incidence of 4153delA BRCA1 gene mutations in Lithuanian breast- and breast-ovarian cancer families. Breast Cancer Res. Treat. 2005, 94, 111–113. [Google Scholar] [CrossRef]
  105. Janavičius, R.; Rudaitis, V.; Mickys, U.; Elsakov, P.; Griškevičius, L. Comprehensive BRCA1 and BRCA2 mutational profile in Lithuania. Cancer Genet. 2014, 207, 195–205. [Google Scholar] [CrossRef]
  106. German Consortium for Hereditary Breast and Ovarian Cancer. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int. J. Cancer 2002, 97, 472–480. [Google Scholar] [CrossRef]
  107. Sokolenko, A.P.; Rozanov, M.E.; Mitiushkina, N.V.; Sherina, N.Y.; Iyevleva, A.G.; Chekmariova, E.V.; Buslov, K.G.; Shilov, E.S.; Togo, A.V.; Bit-Sava, E.M.; et al. Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia. Fam. Cancer 2007, 6, 281–286. [Google Scholar] [CrossRef]
  108. Sokolenko, A.P.; Sokolova, T.N.; Ni, V.I.; Preobrazhenskaya, E.V.; Iyevleva, A.G.; Aleksakhina, S.N.; Romanko, A.A.; Bessonov, A.A.; Gorodnova, T.V.; Anisimova, E.I.; et al. Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients. Breast Cancer Res. Treat. 2020, 184, 229–235. [Google Scholar] [CrossRef]
  109. Incorvaia, L.; Fanale, D.; Badalamenti, G.; Bono, M.; Calò, V.; Cancelliere, D.; Castiglia, M.; Fiorino, A.; Pivetti, A.; Barraco, N.; et al. Hereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily)—Prevalence and Geographic Distribution of Pathogenic Variants in BRCA1/2 Genes. Cancers 2020, 12, 1158. [Google Scholar] [CrossRef]
  110. Rocca, V.; Lo Feudo, E.; Dinatolo, F.; Lavano, S.M.; Bilotta, A.; Amato, R.; D’Antona, L.; Trapasso, F.; Baudi, F.; Colao, E.; et al. Germline Variant Spectrum in Southern Italian High-Risk Hereditary Breast Cancer Patients: Insights from Multi-Gene Panel Testing. Curr. Issues Mol. Biol. 2024, 46, 13003–13020. [Google Scholar] [CrossRef] [PubMed]
  111. Thompson, E.R.; Rowley, S.M.; Li, N.; McInerny, S.; Devereux, L.; Wong-Brown, M.W.; Trainer, A.H.; Mitchell, G.; Scott, R.J.; James, P.A.; et al. Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care. J. Clin. Oncol. 2016, 34, 1455–1459. [Google Scholar] [CrossRef]
  112. Thorlacius, S.; Olafsdottir, G.; Tryggvadottir, L.; Neuhausen, S.; Jonasson, J.G.; Tavtigian, S.V.; Tulinius, H.; Ogmundsdottir, H.M.; Eyfjörd, J.E. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat. Genet. 1996, 13, 117–119. [Google Scholar] [CrossRef] [PubMed]
  113. Sarantaus, L.; Huusko, P.; Eerola, H.; Launonen, V.; Vehmanen, P.; Rapakko, K.; Gillanders, E.; Syrjäkoski, K.; Kainu, T.; Vahteristo, P.; et al. Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland. Eur. J. Hum. Genet. 2000, 8, 757–763. [Google Scholar] [CrossRef] [PubMed]
  114. Akbari, M.R.; Donenberg, T.; Lunn, J.; Curling, D.; Turnquest, T.; Krill-Jackson, E.; Zhang, S.; Narod, S.; Hurley, J. The spectrum of BRCA1 and BRCA2 mutations in breast cancer patients in the Bahamas. Clin. Genet. 2014, 85, 64–67. [Google Scholar] [CrossRef]
  115. Oddoux, C.; Struewing, J.P.; Clayton, C.M.; Neuhausen, S.; Brody, L.C.; Kaback, M.; Haas, B.; Norton, L.; Borgen, P.; Jhanwar, S.; et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat. Genet. 1996, 14, 188–190. [Google Scholar] [CrossRef]
  116. Balabas, A.; Skasko, E.; Nowakowska, D.; Niwinska, A.; Blecharz, P. Novel germline mutations in BRCA2 gene among breast and breast-ovarian cancer families from Poland. Fam. Cancer 2010, 9, 267–274. [Google Scholar] [CrossRef]
  117. Chodick, G.; Struewing, J.P.; Ron, E.; Rutter, J.L.; Iscovich, J. Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: Evidence from 261 cases in Israel, 1976–1999. Eur. J. Med. Genet. 2008, 51, 141–147. [Google Scholar] [CrossRef] [PubMed]
  118. Grzybowska, E.; Zientek, H.; Jasinska, A.; Rusin, M.; Kozlowski, P.; Sobczak, K.; Sikorska, A.; Kwiatkowska, E.; Gorniak, L.; Kalinowska, E.; et al. High frequency of recurrent mutations in BRCA1 and BRCA2 genes in Polish families with breast and ovarian cancer. Hum. Mutat. 2000, 16, 482–490. [Google Scholar] [CrossRef]
  119. Foretova, L.; Machackova, E.; Navratilova, M.; Pavlu, H.; Hruba, M.; Lukesova, M.; Valik, D. BRCA1 and BRCA2 mutations in women with familial or early-onset breast/ovarian cancer in the Czech Republic. Hum. Mutat. 2004, 23, 397–398. [Google Scholar] [CrossRef] [PubMed]
  120. Konecny, M.; Milly, M.; Zavodna, K.; Vavrova, L.; Mlkvá, I.; Ilencikova, D.; Kausitz, J.; Bartošová, Z. Molecular-genetic analysis of hereditary breast/ovarian cancer: Results of mutation testing of BRCA1 and BRCA2 genes; Molekularno-geneticka diagnostika hereditarneho karcinomu prsnika/ovarii: Vysledky testovania mutacii v genoch BRCA1 a BRCA2. Onkologia 2012, 7, 89–93. [Google Scholar]
  121. Kwiatkowska, E.; Teresiak, M.; Lamperska, K.M.; Karczewska, A.; Breborowicz, D.; Stawicka, M.; Godlewski, D.; Krzyzosiak, W.J.; Mackiewicz, A. BRCA2 germline mutations in male breast cancer patients in the Polish population. Hum. Mutat. 2001, 17, 73. [Google Scholar] [CrossRef]
  122. Brozek, I.; Ochman, K.; Debniak, J.; Morzuch, L.; Ratajska, M.; Stepnowska, M.; Stukan, M.; Emerich, J.; Limon, J. High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland. Gynecol. Oncol. 2008, 108, 433–437. [Google Scholar] [CrossRef]
  123. Ratajska, M.; Krygier, M.; Stukan, M.; Kuźniacka, A.; Koczkowska, M.; Dudziak, M.; Śniadecki, M.; Dębniak, J.; Wydra, D.; Brozek, I.; et al. Mutational analysis of BRCA1/2 in a group of 134 consecutive ovarian cancer patients. Novel and recurrent BRCA1/2 alterations detected by next generation sequencing. J. Appl. Genet. 2014, 56, 193–198. [Google Scholar] [CrossRef]
  124. Yanus, G.A.; Savonevich, E.L.; Sokolenko, A.P.; Romanko, A.A.; Ni, V.I.; Bakaeva, E.K.; Gorustovich, O.A.; Bizin, I.V.; Imyanitov, E.N. Founder vs. non-founder BRCA1/2 pathogenic alleles: The analysis of Belarusian breast and ovarian cancer patients and review of other studies on ethnically homogenous populations. Fam. Cancer 2023, 22, 19–30. [Google Scholar] [CrossRef]
  125. Riedlova, P.; Janoutova, J.; Hermanova, B. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic. Mol. Biol. Rep. 2020, 47, 2763–2769. [Google Scholar] [CrossRef]
  126. Sessa, C.; Balmaña, J.; Bober, S.L.; Cardoso, M.J.; Colombo, N.; Curigliano, G.; Domchek, S.; Evans, D.; Fischerova, D.; Harbeck, N.; et al. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. Ann. Oncol. 2023, 34, 33–47. [Google Scholar] [CrossRef] [PubMed]
Cancers 18 00492 g001
Figure 1. Schematic representation of breast cancer risk factors.
Figure 1. Schematic representation of breast cancer risk factors.
Cancers 18 00492 g001
Cancers 18 00492 g002
Figure 2. Sample pedigree of a family. The site of cancer and age of diagnosis are indicated next to the symbol. Squares indicate males and circles indicate females; filled symbols represent affected individuals, while open symbols indicate unaffected individuals; symbols crossed with a diagonal line indicate age at diagnosis; numbers indicate age at diagnosis; BR—breast cancer; OV—ovarian cancer.
Figure 2. Sample pedigree of a family. The site of cancer and age of diagnosis are indicated next to the symbol. Squares indicate males and circles indicate females; filled symbols represent affected individuals, while open symbols indicate unaffected individuals; symbols crossed with a diagonal line indicate age at diagnosis; numbers indicate age at diagnosis; BR—breast cancer; OV—ovarian cancer.
Cancers 18 00492 g002
Cancers 18 00492 g003
Figure 3. Frequency of pathogenic variants in breast cancer in women [29,30,31,32,33]. Percentages may not sum to 100% due to rounding.
Figure 3. Frequency of pathogenic variants in breast cancer in women [29,30,31,32,33]. Percentages may not sum to 100% due to rounding.
Cancers 18 00492 g003
Cancers 18 00492 g004
Figure 4. Prevalence of 5382insC, 300T/G, 185delAG and 3819del5 mutations in the BRCA1 gene in newborns from seven regions of Poland [67] and the most frequent mutations in Poland’s neighbors.
Figure 4. Prevalence of 5382insC, 300T/G, 185delAG and 3819del5 mutations in the BRCA1 gene in newborns from seven regions of Poland [67] and the most frequent mutations in Poland’s neighbors.
Cancers 18 00492 g004
Table 1. Mutations in the BRCA1 gene identified in Polish population [65,66,67,71,72,73,74,92,93,94,95,96,97,98]. N—number of families; n—number of probands.
Table 1. Mutations in the BRCA1 gene identified in Polish population [65,66,67,71,72,73,74,92,93,94,95,96,97,98]. N—number of families; n—number of probands.
Sobczak
[73]		Górski
[65]		Perkowska
[71]		Górski
[74]		Lubiński
[98]		Ratajska
[72]		Brożek
[67]		Gaj
[95]		Cybulski
[94]		Szwiec
[66]		Kluska
[96]		Wójcik
[93]		Rogoza-Janiszewska
[97]		Nguyen-Dumont [92]
n = 236N = 66N = 60N = 200n = 3472N = 64n = 1185n = 906n = 144n = 1164n = 512n = 121n = 2464n = 337
c.5266dupC
(Polish founder mutation)		-186681341735114-39-618424
c.181T>G
(Polish founder mutation)		-73315291838-19-4837
c.4035delA
(Polish founder mutation)		14-1212--2-3--132
c.68_69delAG-211-3-8-5--61
c.5251C>T---1---813--51
c.4501C>T----------1---
c.190T>C-1------------
c.2563C>T--1------------
c.2872_2876delTTTCA-----1--------
c.4357+1G>A--1-----------
c.4516delG----------4---
c.2866_2870delTCTCA---1----------
c.4243G>T----------1---
c.403delAAGA----------1---
c.3700_3704del5-213-4-11-9--9-
c.3817C>T-----1--------
c.340delTC----------1---
c.675delT---2----------
c.3756_3759delGTCT-------4-------
c.5285insG----------1---
c.5344G>A--1-----------
c.3779delT-------2------
c.403delA----------1---
c.5028_5031delGAAA---1----------
c.4041_4042delAG-------11-----
c.5211G>A-------1------
c.1612_1616del-------------1
c.1695insG----------1---
c.5177_5180delGAAA--------1-----
c.5346G>A1-------1-4-11
c.1687C>T--------1-8---
c.4689C>G----------1---
c.843_846del-------------1
c.4597delGA----------1---
c.5232del7ins12----------1---
c.1612C>T----------1---
c.5137delG----------1---
c.3531delT-----------1--
c.314A>G1-------------
c.374dup-------------1
Table 2. Mutations in the BRCA2 gene identified in Polish population [66,68,71,72,74,92,93,94,95,96,97,116,118,121,122,123].
Table 2. Mutations in the BRCA2 gene identified in Polish population [66,68,71,72,74,92,93,94,95,96,97,116,118,121,122,123].
Looij [68]Grzybowska [118]Kwiatkowska [121]Perkowska
[71]		Górski [74]Brożek [122]Ratajska [72]Balabas [116]Gaj [95]Cybulski [94]Ratajska [123]Szwiec [66]Kluska [96]Wójcik [93]Rogoża-Jerzewska [97]Nguyen-Dumont [92]Total
n = 25n = 47n = 37n = 60n = 200n = 151n = 64n = 105n = 906n = 144n = 134n = 1164n = 512n = 121n = 2464n = 337
c.2 T>C---------1------1
c.22_23delAG---------1------1
c.262_263delCT----1-----------1
c.274C>T------------1---1
c.658_659delGT-----------1--1-2
c.700delT------------1---1
c.1180G>T-------11-------2
c.1310_1313delAAGA-------------2--2
c.1318_1321delCTTA------------1---1
c.1813_1814insA--1-------------1
c.2806_2809delAAAC---------1------1
c.2808_2811delACAA----------1-1---2
c.3075_3076delinsTT---------------11
c.3199delA----1-----------1
c.3847_3848delGT1----------1--1-3
c.3860delA---1------------1
c.3975_3981dupTGCT-----1---11-----3
c.4223delA-----1----------1
c.5042_5043delTG----------1---- 1
c.5239_5240insT----1--14--1---18
c.5718_5719delCT---------1------1
c.5946delT-------14--1----6
c.5964_5965delAT-------1--------1
c.6010_6030delinsTT------1---------1
c.6267_6269delGCAinsC--1----------1--2
c.6275_6276delTT---------1------1
c.6393_6396delATTA-----1----------1
c.6402_6406delTAACT---------1------1
c.6447_6448delTA-------1--------1
c.6658_6662delGAAAA-1--------------1
c.7007G>A----1-----------1
c.7180A>T----------1-----1
c.7251_7252delCA---------1--3---4
c.7080_7099dup1--------------12
c.7913_7917delTTCCT--1-1--32--1-1--9
c.8648delC------1--1------2
c.8842delA1---1-------1---3
c.8924delT-------11-------2
c.8946delA------------1---1
c.9027delT-------------1--1
c.9-------1-1------2
c.9118-2A>G-------1----3---4
c.9138C>T------------1---1
c.9253_9254insA---------1-----12
c.9371A>T-11----3----62--13
c.9376delC------------1---1
c.9402delC-3--1--1-1---2--8
c.10095delCinsGAATTATATCT------21-----1--4
c.5857G>T---------------11
c.8623G>T---------------11
c.6315_6318del---------------11
c.9089_9090insA---------1------1
c.9246_9247insA---------1------1
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Kulikowska, B.; Panasiuk, B.; Posmyk, R. Frequency of Founder Mutations in BRCA1 and BRCA2 Genes in Hereditary Breast Cancers in Poland vs. Other Countries. Cancers 2026, 18, 492. https://doi.org/10.3390/cancers18030492

AMA Style

Kulikowska B, Panasiuk B, Posmyk R. Frequency of Founder Mutations in BRCA1 and BRCA2 Genes in Hereditary Breast Cancers in Poland vs. Other Countries. Cancers. 2026; 18(3):492. https://doi.org/10.3390/cancers18030492

Chicago/Turabian Style

Kulikowska, Beata, Barbara Panasiuk, and Renata Posmyk. 2026. "Frequency of Founder Mutations in BRCA1 and BRCA2 Genes in Hereditary Breast Cancers in Poland vs. Other Countries" Cancers 18, no. 3: 492. https://doi.org/10.3390/cancers18030492

APA Style

Kulikowska, B., Panasiuk, B., & Posmyk, R. (2026). Frequency of Founder Mutations in BRCA1 and BRCA2 Genes in Hereditary Breast Cancers in Poland vs. Other Countries. Cancers, 18(3), 492. https://doi.org/10.3390/cancers18030492

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop